← Back to Clinical Trials
Recruiting NCT03470246

NCT03470246 Personalized Activity Intervention in Rehabilitation After Cardiac Operations (the PACO Trial)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03470246
Status Recruiting
Phase —
Sponsor Kuopio University Hospital
Condition Coronary Artery Disease
Study Type INTERVENTIONAL
Enrollment 540 participants
Start Date 2018-04-06
Primary Completion 2022-01

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
PACO intervention for CABG patientsPACO intervention for AVR patientsPACO intervention for MVR patients

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 540 participants in total. It began in 2018-04-06 with a primary completion date of 2022-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The PACO trial is a randomized clinical trial conducted in Heart Centers of Kuopio and Turku university hospitals. The coronary artery disease, aortic valve stenosis and mitral valve insufficiency patients preparing for elective coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or mitral valve repair (MVR) will be randomized to either intervention or control group. The specific operation groups (CABG, AVR and MVR) will be analyzed separately. The 7-day baseline measurements of sedentary behaviour (SB), physical activity (PA) and sleep will be conducted to the patients by using the RM42 accelerometer during the pre-operative month. After the cardiac procedure is completed and the patient is moved to post-operative ward, the control group patients will begin the standard post-operative rehabilitation program of the participating hospitals (activity guidance given by a physiotherapist). Patients in the intervention groups will follow the identical program but after discharge they will also receive personalized activity guidance through the combination of ExSed smart phone application, Suunto MoveSense accelerometer and cloud system during the first 90 days of post-operative rehabilitation. Weekly evolving daily goals to replace SB with PA (daily goals for steps, moderate PA, light PA and standing, and sitting time limit) will be designed for each patient of the intervention groups. A new daily step goal will be delivered from the cloud system to the patient's smart phone in the beginning of each week of the intervention. The daily step goal of the first intervention week is based on patient's walking distance assessed by a physiotherapist in post-operative ward. The following goals will be automatically evolved in the basis of patient's personal average step count of the previous week. The MoveSense accelerometer will measure accumulated levels of SB, PA and sleep, and transmit the data to user's ExSed application with Bluetooth. With information about accumulated levels of SB and PA, the application is able to guide the patient to accomplish the predefined activity goal. The guidance and motivation will be offered with pop-up notifications and histograms (columns are fulfilled according to patient's accumulated daily activity). The researches retain a remote access to the activity data of patients in the cloud system. The ExSed application will be connected to the cloud system with internet connection. In addition, the patients of the intervention groups will receive short video files (lasting from 1 to 3 minutes) containing exercise guidance from a physiotherapist specialized to cardiac operation patients. These videos are available on the ExSed application during the intervention. The physiotherapist will also contact each patient (by mobile phone) with structured contact form from 1 to 4 times in a month to make sure that the intervention is proceeding as designed.

Eligibility Criteria

Inclusion Criteria: * An eligible patient with coronary artery disease, aortic valve stenosis or mitral valve insufficiency scheduled for elective coronary artery bypass grafting, aortic valve replacement or mitral valve repair operation. * He / she does not have any severe disease or functional limitation limiting PA (other than CVD). * He / she is willing to wear a hip- and wrist-worn accelerometer. * He / she is willing and capable to use a smart phone application. Exclusion Criteria: * He / she ends up in prolonged intensive care after cardiac operation. * He / she has a memory disorder (i.e. Alzheimer's disease).

Contact & Investigator

Central Contact

Ville Vasankari, B.M. with thesis

✉ villevas@uef.fi

📞 505208148

Principal Investigator

Jari Halonen, M.D.; Ph.D.

PRINCIPAL INVESTIGATOR

Heart Center, Kuopio University Hospital

Frequently Asked Questions

Who can join the NCT03470246 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 90 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03470246 currently recruiting?

Yes, NCT03470246 is actively recruiting participants. Contact the research team at villevas@uef.fi for enrollment information.

Where is the NCT03470246 trial being conducted?

This trial is being conducted at Kuopio, Finland.

Who is sponsoring the NCT03470246 clinical trial?

NCT03470246 is sponsored by Kuopio University Hospital. The principal investigator is Jari Halonen, M.D.; Ph.D. at Heart Center, Kuopio University Hospital. The trial plans to enroll 540 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology